NI201500031A - Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos. - Google Patents

Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos.

Info

Publication number
NI201500031A
NI201500031A NI201500031A NI201500031A NI201500031A NI 201500031 A NI201500031 A NI 201500031A NI 201500031 A NI201500031 A NI 201500031A NI 201500031 A NI201500031 A NI 201500031A NI 201500031 A NI201500031 A NI 201500031A
Authority
NI
Nicaragua
Prior art keywords
methods
disease
same
pharmaceutical compositions
treat alzheimer
Prior art date
Application number
NI201500031A
Other languages
English (en)
Spanish (es)
Inventor
Schmidt Ellen
Areberg Johan
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49118521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201500031(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of NI201500031A publication Critical patent/NI201500031A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NI201500031A 2012-09-09 2015-03-06 Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos. NI201500031A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261698664P 2012-09-09 2012-09-09
US201361782084P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
NI201500031A true NI201500031A (es) 2016-02-15

Family

ID=49118521

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500031A NI201500031A (es) 2012-09-09 2015-03-06 Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos.

Country Status (33)

Country Link
US (4) US9375418B2 (enExample)
EP (1) EP2892563B1 (enExample)
JP (2) JP6693744B2 (enExample)
KR (2) KR102342127B1 (enExample)
CN (1) CN104619344A (enExample)
AP (1) AP2015008306A0 (enExample)
AU (1) AU2013311573B2 (enExample)
BR (1) BR112015005117B1 (enExample)
CA (1) CA2883751C (enExample)
CL (1) CL2015000578A1 (enExample)
CY (1) CY1121062T1 (enExample)
DK (1) DK2892563T3 (enExample)
EA (1) EA030448B1 (enExample)
ES (1) ES2703630T3 (enExample)
GE (1) GEP201706776B (enExample)
HR (1) HRP20182069T1 (enExample)
IL (1) IL237369B (enExample)
JO (1) JO3459B1 (enExample)
LT (1) LT2892563T (enExample)
MX (1) MX368305B (enExample)
MY (1) MY182539A (enExample)
NI (1) NI201500031A (enExample)
NZ (1) NZ630589A (enExample)
PL (1) PL2892563T3 (enExample)
PT (1) PT2892563T (enExample)
RS (1) RS58104B1 (enExample)
RU (1) RU2675786C2 (enExample)
SG (1) SG11201501774QA (enExample)
SI (1) SI2892563T1 (enExample)
SM (1) SMT201800678T1 (enExample)
TN (1) TN2015000076A1 (enExample)
TW (1) TWI632909B (enExample)
WO (1) WO2014037532A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1558582T3 (da) 2003-07-22 2006-05-08 Arena Pharm Inc Diaryl og arylheteroarylureaderivater som modulatorer af aktiviteten af 5-HT2A-serotoninreceptoren anvendelige til profylakse eller behandling af forstyrrelser relateret dertil
WO2009074607A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 P2x7調控劑
PE20151727A1 (es) 2013-03-14 2015-12-17 Boehringer Ingelheim Int Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
JP6467404B2 (ja) 2013-03-14 2019-02-13 ヤンセン ファーマシューティカ エヌ.ベー. P2x7モジュレーター
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 P2x7調節劑
EP3112366B1 (en) 2013-03-14 2018-02-28 Janssen Pharmaceutica NV P2x7 modulators
JO3639B1 (ar) 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
MX367316B (es) 2014-09-12 2019-08-15 Boehringer Ingelheim Int Inhibidores espirociclicos de catepsina c.
US10150766B2 (en) 2014-09-12 2018-12-11 Janssen Pharmaceutica Nv P2X7 modulators
EA201790600A1 (ru) 2014-09-12 2017-07-31 Янссен Фармацевтика Нв Модулирующие p2x7 n-ацил-триазолопиразины
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
US20160324852A1 (en) * 2015-05-07 2016-11-10 Axovant Sciences Ltd. Compositions and methods of treating a neurodegenerative disease
EP3307260A4 (en) 2015-06-12 2019-02-13 Axovant Sciences GmbH DIARYL AND ARYLHETEROARYL UREA DERIVATIVES FOR PROPHYLAXIS AND TREATMENT OF SLEEP BEHAVIORAL DISORDERS IN THE REM PHASE
MX391031B (es) 2015-07-15 2025-03-21 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor de serotonina 5-ht2a útiles para la profilaxis y el tratamiento de alucinaciones asociadas con una enfermedad neurodegenerativa.
AU2017256623B2 (en) * 2016-04-26 2022-07-21 H. Lundbeck A/S Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in Parkinson's disease patients
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
PT3484467T (pt) 2016-05-18 2020-06-16 Suven Life Sciences Ltd Combinação de antagonistas puros do recetor 5-ht6 com inibidores de acetilcolinesterase
CN106309436A (zh) * 2016-07-25 2017-01-11 宁波大学 可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途
CN107118146B (zh) * 2017-04-13 2019-09-03 宁波大学 一种6-溴色胺衍生物及其制备方法和用途
LT3630098T (lt) 2017-05-24 2021-05-25 H. Lundbeck A/S 5-ht6 receptoriaus antagonisto ir acetilcholinesterazės inhibitoriaus derinys, skirtas naudoti gydant alzheimerio ligą pacientų pogrupyje, turiančiame apoe4 aliejus
TWI863931B (zh) 2018-09-28 2024-12-01 比利時商健生藥品公司 單醯基丙三醇脂酶調節劑
AU2019349962A1 (en) 2018-09-28 2021-03-18 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
ES3037365T3 (en) 2019-09-30 2025-10-01 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
EP4126860A1 (en) 2020-03-26 2023-02-08 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
EP3960174B1 (en) 2020-08-28 2024-10-30 Westfälische Wilhelms-Universität Münster Parasympathetic active phenyl-glycosid-substituted hydroxy-methyl-piperidine and -pyrrolidine alkaloids for medicinal use
CN121013715A (zh) * 2024-03-22 2025-11-25 艾瑞克·奎因 镁和利多卡因组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3597149A (en) 1969-04-29 1971-08-03 Showa Denko Kk Inhibition of gas-fume fading of dyed cellulose acetate material
FR2181559A1 (en) 1972-04-28 1973-12-07 Aec Chimie Organique Bio N-Phenylalkyl-N-3-indolylalkyl-alkylamines - with sedative, neuroleptic, analgesic, hypotensive, antiserotonin, adrenolytic activity
JPS5764632A (en) 1980-10-09 1982-04-19 Mitsui Toatsu Chem Inc Novel 2-arylethyl ether derivative and thioether derivative, their production and insecticide and acaricide
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
WO1995006638A1 (en) 1993-09-01 1995-03-09 Allelix Biopharmaceuticals Inc. Tryptamine analogs with 5-ht1d selectivity
US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
PT1032559E (pt) 1997-09-29 2007-02-28 Aventis Pharma Inc Derivados de aminoalquilfenol para tratamento de depressão e disfunção da memória
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
ATE319683T1 (de) 1998-12-11 2006-03-15 Univ Virginia Commonwealth Selektive 5-ht 6-rezeptor-liganden
OA11820A (en) 1999-01-13 2005-08-17 Warner Lambert Co Functionalized heterocycles as chemokine receptor modulators.
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
US7157488B2 (en) * 2001-03-29 2007-01-02 Eli Lilly And Company N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor
RU2252936C2 (ru) * 2002-12-05 2005-05-27 Институт физиологически активных веществ РАН S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты)
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
CN101500611A (zh) 2006-06-23 2009-08-05 埃斯蒂维实验室股份有限公司 胆碱脂酶抑制剂与具有5-ht6受体亲和力的化合物的组合
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
MX2012000939A (es) * 2009-07-23 2012-06-08 Shire Llc Profarmacos de peptidos y aminoacidos de galantamina y usos de los mismos.
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
SG11201501774QA (en) 2015-05-28
DK2892563T3 (en) 2019-01-21
US9375418B2 (en) 2016-06-28
MX368305B (es) 2019-09-27
MY182539A (en) 2021-01-25
RS58104B1 (sr) 2019-02-28
MX2015002879A (es) 2015-07-06
US9687473B2 (en) 2017-06-27
BR112015005117A2 (pt) 2017-07-04
EA030448B1 (ru) 2018-08-31
CN104619344A (zh) 2015-05-13
JP2019059760A (ja) 2019-04-18
RU2675786C2 (ru) 2018-12-25
US20160256437A1 (en) 2016-09-08
KR20150065680A (ko) 2015-06-15
US9789085B2 (en) 2017-10-17
SI2892563T1 (sl) 2019-02-28
HK1212217A1 (en) 2016-06-10
IL237369B (en) 2018-11-29
CL2015000578A1 (es) 2015-05-15
US20140073681A1 (en) 2014-03-13
SMT201800678T1 (it) 2019-02-28
AP2015008306A0 (en) 2015-03-31
TWI632909B (zh) 2018-08-21
NZ630589A (en) 2015-12-24
RU2015107877A (ru) 2016-10-27
KR20200137028A (ko) 2020-12-08
CY1121062T1 (el) 2019-12-11
GEP201706776B (en) 2017-11-27
EP2892563B1 (en) 2018-11-14
JP2015528471A (ja) 2015-09-28
TN2015000076A1 (en) 2016-06-29
AU2013311573A1 (en) 2015-03-12
PL2892563T3 (pl) 2019-04-30
JP6693744B2 (ja) 2020-05-13
CA2883751A1 (en) 2014-03-13
HRP20182069T1 (hr) 2019-02-08
PT2892563T (pt) 2019-01-10
EA201590353A1 (ru) 2016-03-31
EP2892563A1 (en) 2015-07-15
IL237369A0 (en) 2015-04-30
KR102342127B1 (ko) 2021-12-21
AU2013311573A8 (en) 2015-03-19
US20160354343A1 (en) 2016-12-08
ES2703630T3 (es) 2019-03-11
JO3459B1 (ar) 2020-07-05
TW201414474A (zh) 2014-04-16
AU2013311573B2 (en) 2017-10-12
BR112015005117B1 (pt) 2022-06-21
CA2883751C (en) 2020-11-24
LT2892563T (lt) 2019-01-10
US20180071254A1 (en) 2018-03-15
US10660878B2 (en) 2020-05-26
WO2014037532A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
NI201500031A (es) Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos.
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
ECSP16072941A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
EA201892219A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
EA201892200A1 (ru) Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
CR20190361A (es) Dendrímeros terapéuticos
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
PH12015502365A1 (en) Bace1 inhibitors
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EA201790315A1 (ru) Модуляторы x-рецепторов печени
MX377032B (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
MX2016008968A (es) Compuestos organicos.
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
CL2017002229A1 (es) Inhibidores de bace1.
AR105400A1 (es) Inhibidores de jak1
BR112015028884A2 (pt) tratamento ou prevenção de depressão utilizando mentol e/ou icilina
NZ727251A (en) Novel polymorphic form of n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of alzheimer’s